Welcome to our dedicated page for Cerevel Therapeutics Holdings news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). Formed in 2018 through a partnership between Bain Capital and Pfizer, Cerevel is headquartered in Cambridge, Massachusetts. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases using a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.
Cerevel's pipeline includes five clinical-stage investigational therapies and several preclinical compounds targeting a range of CNS disorders, such as Parkinson’s disease, Alzheimer’s disease psychosis, epilepsy, schizophrenia, and addiction. The company’s lead programs include:
- Emraclidine: An M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer’s disease psychosis.
- Darigabat: An α2/3/5-selective GABAA receptor PAM currently under development for epilepsy and panic disorder.
- Tavapadon: A D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.
- CVL-871: A D1/D5 partial agonist in development for treatment of dementia-related apathy.
In recent news, Cerevel announced the pricing of its underwritten public offering, where it successfully raised approximately $450 million. Additionally, Cerevel reported positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease. The company is also advancing its early clinical pipeline and discovery programs while exploring new modalities through internal research, external collaborations, or potential acquisitions.
On December 6, 2023, Cerevel announced its acquisition by AbbVie Inc. (NYSE: ABBV). The transaction, valued at approximately $8.7 billion, aims to bolster AbbVie’s neuroscience portfolio with Cerevel’s robust pipeline of therapies. The acquisition is expected to close by mid-2024, subject to regulatory approvals and other customary conditions.
Cerevel continues to drive forward with its mission, leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity to develop innovative treatments for neuroscience diseases, ultimately aiming to improve patient outcomes and quality of life.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO, Tony Coles, M.D., will present at the 2023 BofA Securities Health Care Conference on May 10th at 10:00 am PT (1:00 pm ET). The presentation will be accessible via a live webcast on the investor relations section of the Cerevel website, with a replay available afterwards.
Cerevel focuses on treating neuroscience diseases by leveraging expertise in neurocircuitry and receptor subtype selectivity. The company has a diversified pipeline that includes five clinical-stage investigational therapies and preclinical compounds aimed at conditions such as schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease.
Cerevel Therapeutics (Nasdaq: CERE) has announced it will report its first quarter 2023 financial results and business updates on May 3, 2023, before the U.S. markets open. A conference call to discuss these results is scheduled for the same day at 8:00 a.m. ET, which will be accessible via registration. Cerevel is focused on treating neuroscience diseases and has a diversified pipeline with five clinical-stage investigational therapies aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. The company emphasizes its commitment to advancing research and development while exploring new avenues through collaborations or acquisitions. More details are available on their investor website.
FAQ
What is the current stock price of Cerevel Therapeutics Holdings (CERE)?
What is the market cap of Cerevel Therapeutics Holdings (CERE)?
What does Cerevel Therapeutics Holdings, Inc. specialize in?
When was Cerevel Therapeutics formed?
Where is Cerevel Therapeutics headquartered?
What are some of Cerevel Therapeutics' leading investigational therapies?
What is the significance of Cerevel’s recent Phase 3 TEMPO-3 trial results?
What recent financial achievement has Cerevel accomplished?
What major acquisition was announced involving Cerevel Therapeutics?
What is the expected closing date for the AbbVie acquisition of Cerevel?
What is Cerevel Therapeutics' approach to treating neuroscience diseases?
Who are the contacts for media and investor inquiries at Cerevel Therapeutics?
